|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-7-5
|
|
pubmed:abstractText |
The cytotoxic effect of trastuzumab in combination with oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2 (HER2)-overexpressing human pancreatic cancer cell line TRG in vitro and in vivo was investigated. HER2 expression in TRG was analyzed by RT-PCR and flow cytometry. For in vitro experiments, 5-fluorouracil (5-FU) was used instead of S-1. In vivo studies were conducted with TRG xenografts in athymic mice. Trastuzumab (10 mg/kg) was administered intraperitoneally once a week for 4 weeks. S-1 (10 mg/kg) was administered orally 5 days a week for 4 weeks. The results showed that TRG cells were positive for HER2 mRNA and overexpressed HER2 protein. Either trastuzumab or 5-FU concentration-dependently inhibited the growth of TRG cells. The combination of trastuzumab and 5-FU resulted in a significant inhibition of growth of TRG cells compared to either agent alone (P<0.001). Incubation of TRG cells with peripheral blood mononuclear cells after treatment with trastuzumab enhanced the antiproliferative effect of trastuzumab, which could be the result of antibody-dependent cellular cytotoxicity. The combination of trastuzumab and S-1 resulted in a significant reduction in xenograft volume compared to each agent alone (P<0.0001). In conclusion, this study showed that combination therapy with trastuzumab and S-1 may be effective for HER2-overexpressing pancreatic cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-3,
http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination),
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/receptor tyrosine-protein kinase...,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1021-335X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
433-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17611667-Administration, Oral,
pubmed-meshheading:17611667-Animals,
pubmed-meshheading:17611667-Antibodies, Monoclonal,
pubmed-meshheading:17611667-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17611667-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17611667-Cell Line, Tumor,
pubmed-meshheading:17611667-Cell Proliferation,
pubmed-meshheading:17611667-Coculture Techniques,
pubmed-meshheading:17611667-Dose-Response Relationship, Drug,
pubmed-meshheading:17611667-Drug Combinations,
pubmed-meshheading:17611667-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17611667-Humans,
pubmed-meshheading:17611667-Leukocytes, Mononuclear,
pubmed-meshheading:17611667-Male,
pubmed-meshheading:17611667-Mice,
pubmed-meshheading:17611667-Mice, Inbred BALB C,
pubmed-meshheading:17611667-Mice, Nude,
pubmed-meshheading:17611667-Oxonic Acid,
pubmed-meshheading:17611667-Pancreatic Neoplasms,
pubmed-meshheading:17611667-RNA, Messenger,
pubmed-meshheading:17611667-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17611667-Receptor, erbB-2,
pubmed-meshheading:17611667-Receptor, erbB-3,
pubmed-meshheading:17611667-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17611667-Tegafur,
pubmed-meshheading:17611667-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
|
|
pubmed:affiliation |
Department of General Surgery, Yokohama City University, Kanagawa 236-0004, Japan. saekihiroyuki@yahoo.co.jp
|
|
pubmed:publicationType |
Journal Article
|
